This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kitakaze, M. Articles by Hori, M. Search for Related Content PubMed PubMed Citation Articles by Kitakaze, M. Articles by Hori, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Hazardous Substances DB THEOPHYLLINE

(Circulation. 1997;95:2108-2114.)
© 1997 American Heart Association, Inc.

Articles

Vesnarinone Limits Infarct Size via Adenosine-Dependent Mechanisms in the Canine Heart

Masafumi Kitakaze, MD; Tetsuo Minamino, MD; Hiroharu Funaya, MD; Koichi Node, MD; Yoshiro Shinozaki, BS; Hidezo Mori, MD; Masatsugu Hori, MD

From the First Department of Medicine, Osaka University School of Medicine, Suita (M.K., T.M., H.F., K.N., M.H.), and Tokai University School of Medicine, Department of Physiology, Isehara (Y.S., H.M.), Japan.

Correspondence to Masafumi Kitakaze, MD, PhD, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan.

Background Recently, vesnarinone, a synthetic inotropic agent, was reported to inhibit adenosine transport into cells, which may increase adenosine levels in the heart and in turn mediate cardioprotection. Thus, vesnarinone may also have protective effects in sustained ischemia-reperfusion, because adenosine limits infarct size.

Methods and Results In open-chest dogs, the left anterior descending coronary arteries were occluded for 90 minutes followed by 6 hours of reperfusion. Vesnarinone limited infarct size compared with controls (6.8±2.2% versus 44.7±3.9%), which was completely reversed by a nonselective adenosine receptor antagonist, 8-sulfophenyltheophylline (44.1±6.8%), and partially blunted by an inhibitor of ecto-5'-nucleotidase, ,ß-methyleneadenosine 5'-diphosphate (AMP-CP, 28.9±4.7%). Dipyridamole, an inhibitor of adenosine uptake into cells, only modestly limited infarct size (27.4±5.5%). Furthermore, vesnarinone increased adenosine release during coronary hypoperfusion, which was attenuated by AMP-CP. In vitro, vesnarinone increased the activity of ecto-5'-nucleotidase of the myocardium.

Conclusions We conclude that vesnarinone potently limits infarct size via adenosine-dependent mechanisms, mainly through activation of ecto-5'-nucleotidase.

Key Words: ischemia • reperfusion • adenosine • myocardial infarction • coronary disease

This article has been cited by other articles:

				M. E. Reichelt, L. Willems, J. G. Molina, C.-X. Sun, J. C. Noble, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick Genetic Deletion of the A1 Adenosine Receptor Limits Myocardial Ischemic Tolerance Circ. Res., February 18, 2005; 96(3): 363 - 367. [Abstract] [Full Text] [PDF]

				S. Sanada, H. Asanuma, T. Minamino, K. Node, S. Takashima, H. Okuda, Y. Shinozaki, A. Ogai, M. Fujita, A. Hirata, et al. Optimal Windows of Statin Use for Immediate Infarct Limitation: 5'-Nucleotidase as Another Downstream Molecule of Phosphatidylinositol 3-Kinase Circulation, October 12, 2004; 110(15): 2143 - 2149. [Abstract] [Full Text] [PDF]

				J. A. Auchampach, X. Jin, J. Moore, T. C. Wan, L. M. Kreckler, Z.-D. Ge, J. Narayanan, E. Whalley, W. Kiesman, B. Ticho, et al. Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 846 - 856. [Abstract] [Full Text] [PDF]

				M. B. Forman, J. V. Vitola, C. E. Velasco, J. J. Murray, R. K. Dubey, and E. K. Jackson Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoattractant Response J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 929 - 938. [Abstract] [Full Text]

				J. R. Kersten, M. W. Montgomery, P. S. Pagel, and D. C. Warltier Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP Channels Anesth. Analg., January 1, 2000; 90(1): 5 - 5. [Abstract] [Full Text] [PDF]

				S. Ishiyama, M. Hiroe, T. Nishikawa, T. Shimojo, T. Hosokawa, I. Ikeda, T. Toyozaki, T. Kasajima, and F. Marumo Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats Cardiovasc Res, August 1, 1999; 43(2): 389 - 397. [Abstract] [Full Text] [PDF]

				S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res, June 1, 1999; 42(3): 557 - 564. [Full Text] [PDF]

				R. S. Vander Heide and J. D. Marsh Through the Looking Glass: A Positive Inotropic Drug and Ischemic Preconditioning Circulation, April 15, 1997; 95(8): 1989 - 1991. [Full Text]